ZIVO Bioscience Statistics
Total Valuation
ZIVO Bioscience has a market cap or net worth of 70.69 million. The enterprise value is 69.40 million.
| Market Cap | 70.69M |
| Enterprise Value | 69.40M |
Important Dates
The next estimated earnings date is Monday, May 12, 2025.
| Earnings Date | May 12, 2025 |
| Ex-Dividend Date | n/a |
Share Statistics
ZIVO Bioscience has 3.76 million shares outstanding. The number of shares has increased by 87.41% in one year.
| Current Share Class | n/a |
| Shares Outstanding | 3.76M |
| Shares Change (YoY) | +87.41% |
| Shares Change (QoQ) | +3.92% |
| Owned by Insiders (%) | 38.76% |
| Owned by Institutions (%) | 0.01% |
| Float | 1.31M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 449.59 |
| PB Ratio | -137.28 |
| P/TBV Ratio | n/a |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | -5.18 |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.80
| Current Ratio | 0.80 |
| Quick Ratio | 0.76 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -582.50 |
Financial Efficiency
| Return on Equity (ROE) | n/a |
| Return on Assets (ROA) | -759.60% |
| Return on Invested Capital (ROIC) | n/a |
| Return on Capital Employed (ROCE) | 3,351.37% |
| Revenue Per Employee | 22,460 |
| Profits Per Employee | -1.91M |
| Employee Count | 7 |
| Asset Turnover | 0.14 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +187.02% in the last 52 weeks. The beta is -0.07, so ZIVO Bioscience's price volatility has been lower than the market average.
| Beta (5Y) | -0.07 |
| 52-Week Price Change | +187.02% |
| 50-Day Moving Average | 17.60 |
| 200-Day Moving Average | 16.72 |
| Relative Strength Index (RSI) | 59.09 |
| Average Volume (20 Days) | 584 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 59.11 |
Income Statement
In the last 12 months, ZIVO Bioscience had revenue of 157,220 and -13.38 million in losses. Loss per share was -4.23.
| Revenue | 157,220 |
| Gross Profit | 48,952 |
| Operating Income | -13.36M |
| Pretax Income | -13.38M |
| Net Income | -13.38M |
| EBITDA | n/a |
| EBIT | -13.36M |
| Loss Per Share | -4.23 |
Balance Sheet
The company has 1.54 million in cash and 254,361 in debt, giving a net cash position of 1.29 million or 0.34 per share.
| Cash & Cash Equivalents | 1.54M |
| Total Debt | 254,361 |
| Net Cash | 1.29M |
| Net Cash Per Share | 0.34 |
| Equity (Book Value) | -514,897 |
| Book Value Per Share | -0.14 |
| Working Capital | -406,380 |
Cash Flow
| Operating Cash Flow | -4.31M |
| Capital Expenditures | n/a |
| Free Cash Flow | n/a |
| FCF Per Share | n/a |
Margins
| Gross Margin | 31.14% |
| Operating Margin | -8,498.85% |
| Pretax Margin | -8,513.44% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
ZIVO Bioscience does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -87.41% |
| Shareholder Yield | -87.41% |
| Earnings Yield | -18.94% |
| FCF Yield | n/a |
Stock Splits
The last stock split was on October 27, 2023. It was a reverse split with a ratio of 0.1666667.
| Last Split Date | Oct 27, 2023 |
| Split Type | Reverse |
| Split Ratio | 0.1666667 |
Scores
ZIVO Bioscience has an Altman Z-Score of -132.98. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -132.98 |
| Piotroski F-Score | n/a |